Genmab — December 2020

[Bulder]

Og 91% ORR i dlbcl ser fint ud.

[JørgenVarnæs]

Godt med CR’er umiddelbart - og imponerende ORR’er

[GeorgeBest]

SQ Epcoritamab...What an impressive BiAB ! Excellent response, SQ administration, very low grade CRS ! The race is on for
BiABs...THE future in B-NHL treatments

[GeorgeBest]

https://twitter.com/lymphoma_md/status/1335685240547921920?s=21

[Bulder]

Den er hjemme

[GeorgeBest]

Konsensus blandt onkologer er at det er rigtig godt

[E_L]

it does look really good, safety also https://twitter.com/lymphomahub/status/1335686290805837828/photo/4

[Bulder]

Best in class?

[JørgenVarnæs]

Better than the comparison nos we saw on Friday

[E_L]

so also Mantle Cell Lymphoma. and already a CR seen there

[E_L]

it would be nice to see the webcast , the way JNJ organised it is really nice

[E_L]

so no CRS events at the second full dose at RP2D

[Vitus]

Dejlig søndag aften....håber mandag også bliver god -:)

[GeorgeBest]

Hutchings glofitamab præsentation https://twitter.com/graham74gc/status/1335689743347179527?s=21

[GeorgeBest]

epcos safety bedre

[GeorgeBest]

mange grade 3-4 AEs hos glofitamab

[E_L]

and we are not even putting any attention here to the Dara data coming out today -which all looks good as well

[GeorgeBest]

Begge Roche cd3/cd20 bsabs har grade 3-4 AEs. Safety må klart være til epcos fordel

[mobbyduck1]

det ser så fint ud med Epco. Helt utrolig track record Genmab har.

[Bulder]

Og sc adm og høj rr.